TABLE 2.
Variables | Total | Type B2 | Type B2 + B3 | Type B3 |
---|---|---|---|---|
Residual disease | ||||
R0 | 217 (91.9%) | 128 (96.2%) | 36 (92.3%) | 53 (82.8%) |
R1/R2 | 7 (3.0%) | 1 (0.8%) | 1 (2.6%) | 5 (7.8%) |
Progression | ||||
Yes | 23 (9.7%) | 12 (9.0%) | 4 (10.3%) | 7 (10.9%) |
No | 203 (86.0%) | 113 (85.0%) | 34 (87.2%) | 56 (87.5%) |
Postoperative therapy | ||||
Radiotherapy | 107 (45.3%) | 54 (40.6%) | 17 (43.6%) | 36 (56.3%) |
Chemotherapy | 14 (5.9%) | 3 (2.3%) | 6 (15.4%) | 5 (7.8%) |
Concurrent chemoradiation | 2 (0.8%) | 1 (0.8%) | 1 (2.6%) | 0 (0.0%) |
Chemotherapy + radiotherapy | 7 (3.0%) | 0 (0.0%) | 2 (5.1%) | 5 (7.8%) |
Radiotherapy + chemotherapy | 9 (3.8%) | 3 (2.3%) | 1 (2.6%) | 5 (7.8%) |
None | 85 (36.0%) | 62 (46.6%) | 11 (28.2%) | 12 (18.8%) |